BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38184753)

  • 1. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
    Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
    Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative genetic alterations of MYC, BCL2, and/or BCL6 in high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL): Can we identify different prognostic subgroups?
    Blomme S; De Paepe P; Devos H; Emmerechts J; Snauwaert S; Cauwelier B
    Genes Chromosomes Cancer; 2024 Jan; 63(1):e23211. PubMed ID: 37897298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.
    Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L
    Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Grade B-Cell Lymphoma (HGBL) with
    Tsai CC; Su YC; Bamodu OA; Chen BJ; Tsai WC; Cheng WH; Lee CH; Hsieh SM; Liu ML; Fang CL; Lin HT; Chen CL; Yeh CT; Lee WH; Ho CL; Lai SW; Tzeng HE; Hsieh YY; Chang CL; Zheng YM; Liu HW; Yen Y; Whang-Peng J; Chao TY
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.
    Yuan CT; Chuang SS; Cheng PY; Chang K; Wang H; Tsai JH; Liau JY; Chou WC
    J Pathol Clin Res; 2022 Sep; 8(5):436-447. PubMed ID: 35715938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.
    Lucioni M; Pescia C; Bonometti A; Fraticelli S; Moltrasio C; Ramponi A; Riboni R; Roccio S; Ferrario G; Arcaini L; Goteri G; Berti E; Paulli M
    Hum Pathol; 2021 May; 111():1-9. PubMed ID: 33548250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognosis of
    Clipson A; Barrans S; Zeng N; Crouch S; Grigoropoulos NF; Liu H; Kocialkowski S; Wang M; Huang Y; Worrillow L; Goodlad J; Buxton J; Neat M; Fields P; Wilkins B; Grant JW; Wright P; Ei-Daly H; Follows GA; Roman E; Watkins AJ; Johnson PW; Jack A; Du MQ
    J Pathol Clin Res; 2015 Jul; 1(3):125-133. PubMed ID: 27347428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
    Pina-Oviedo S; Bellamy WT; Gokden M
    Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
    Hilton LK; Collinge BJ; Ben-Neriah S; Alduaij W; Shaalan H; Weng A; Cruz M; Slack GW; Farinha P; Miyata-Takata T; Boyle M; Meissner B; Cook JR; Ondrejka SL; Ott G; Rosenwald A; Campo E; Amador C; Greiner TC; Raess PW; Song JY; Inghirami GG; Jaffe ES; Weisenburger DD; Chan WC; Beiske K; Fu K; Delabie J; Pittaluga S; Iqbal J; Wright G; Sehn LH; Savage KJ; Mungall AJ; Feldman AL; Staudt LM; Steidl C; Rimsza LM; Morin RD; Scott DW
    Blood; 2024 May; ():. PubMed ID: 38701426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic and pathologic characterization of MYC-rearranged B-cell lymphomas in pediatric and young adult patients.
    Gagnon MF; Bruehl FK; Sill DR; Meyer RG; Greipp PT; Hoppman NL; Xu X; Baughn LB; Peterson JF; McPhail ED; Ketterling RP; King RL
    J Hematop; 2024 Jun; 17(2):51-61. PubMed ID: 38561469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of high-grade B-cell lymphoma with
    Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
    Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes.
    Kikuchi A; Nakamura N; Kuze T; Sasaki Y; Abe M; Ohno H; Akasaka T; Nakamura S; Ohshima K; Ando K
    Leuk Res; 2008 Aug; 32(8):1176-82. PubMed ID: 18460403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.